HK1169408A1 - Cdk inhibitor salts cdk - Google Patents

Cdk inhibitor salts cdk

Info

Publication number
HK1169408A1
HK1169408A1 HK12110192.1A HK12110192A HK1169408A1 HK 1169408 A1 HK1169408 A1 HK 1169408A1 HK 12110192 A HK12110192 A HK 12110192A HK 1169408 A1 HK1169408 A1 HK 1169408A1
Authority
HK
Hong Kong
Prior art keywords
cdk
inhibitor salts
salts
inhibitor
cdk inhibitor
Prior art date
Application number
HK12110192.1A
Other languages
English (en)
Chinese (zh)
Inventor
．贊姆皮裡
．艾羅爾迪
．弗納雷托
．布拉斯卡
Original Assignee
內爾維阿諾醫學科學有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 內爾維阿諾醫學科學有限公司 filed Critical 內爾維阿諾醫學科學有限公司
Publication of HK1169408A1 publication Critical patent/HK1169408A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
HK12110192.1A 2009-04-29 2012-10-16 Cdk inhibitor salts cdk HK1169408A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09159030 2009-04-29
PCT/EP2010/055463 WO2010125004A1 (en) 2009-04-29 2010-04-23 Cdk inhibitor salts

Publications (1)

Publication Number Publication Date
HK1169408A1 true HK1169408A1 (en) 2013-01-25

Family

ID=42199163

Family Applications (1)

Application Number Title Priority Date Filing Date
HK12110192.1A HK1169408A1 (en) 2009-04-29 2012-10-16 Cdk inhibitor salts cdk

Country Status (9)

Country Link
US (1) US8586598B2 (de)
EP (1) EP2424868B1 (de)
JP (1) JP5801285B2 (de)
CN (1) CN102428086B (de)
AR (1) AR076433A1 (de)
ES (1) ES2660146T3 (de)
HK (1) HK1169408A1 (de)
TW (1) TW201043631A (de)
WO (1) WO2010125004A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2668188B1 (de) * 2011-01-26 2016-05-18 Nerviano Medical Sciences S.r.l. Tricyclische derivate, verfahren zu ihrer herstellung und ihre verwendung als kinasehemmer
ES2602791T3 (es) * 2011-01-26 2017-02-22 Nerviano Medical Sciences S.R.L. Derivados de pirrolo tricíclicos, proceso para su preparación y su uso como inhibidores de cinasa
SI3057965T1 (sl) * 2013-10-18 2019-04-30 University Health Network Sol in kristalne oblike inhibitorja PLK-4
USRE50082E1 (en) 2014-04-07 2024-08-20 Netherlands Translational Research Center B.V. (5,6-dihydro)pyrimido[4,5-e]indolizines
CN115160402A (zh) 2016-03-11 2022-10-11 隐形生物治疗公司 结晶盐形式
CN107216340B (zh) * 2016-03-22 2021-05-04 中国科学院上海药物研究所 一种dppiv抑制剂的盐型及其制备方法
CN107216339B (zh) * 2016-03-22 2021-05-04 中国科学院上海药物研究所 一种dppiv抑制剂马来酸盐的多晶型及其制备方法
EP3606938A1 (de) 2017-04-05 2020-02-12 Stealth BioTherapeutics Corp Kristalline salzformen von boc-d-arg-dmt-lys-(boc)-phe-nh2
US10676506B2 (en) 2018-01-26 2020-06-09 Stealth Biotherapeutics Corp. Crystalline bis- and tris-hydrochloride salt of elamipretide
CN110092775B (zh) * 2018-01-29 2021-09-10 轩竹生物科技有限公司 靶向cdk4/6激酶抑制剂的晶型
EA202091556A1 (ru) * 2018-01-29 2021-02-19 Сюаньчжу (Хайнань) Биофармасьютикал Ко., Лтд. Кристаллическая форма ингибитора киназы cdk4/6
CN109632555B (zh) * 2018-12-28 2021-07-27 上海新黄河制药有限公司 一种富马酸福莫特罗无定型含量的动态蒸汽吸附分析方法
CN112010839B (zh) * 2019-05-31 2022-06-17 轩竹生物科技股份有限公司 靶向丝/苏氨酸激酶抑制剂的晶型

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030100594A1 (en) * 2001-08-10 2003-05-29 Pharmacia Corporation Carbonic anhydrase inhibitor
GEP20094664B (en) * 2003-05-22 2009-04-10 Nerviano Medical Sciences Srl Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors
EP1986632B1 (de) * 2006-02-10 2012-08-15 Nerviano Medical Sciences S.R.L. Kombinationen mit einen cdk-hemmer und einem wachstumsfaktorantiköprer oder antimitotikum
EP2019101A1 (de) * 2007-07-26 2009-01-28 GPC Biotech AG Pyrazol[3,4-d]pyrimidin-4-one nützlich als Kinase-Inhibitor
US8138336B2 (en) * 2007-09-25 2012-03-20 Bayer Healthcare Llc Pyrrolotriazine derivatives useful for treating cancer through inhibition of aurora kinase
US8022216B2 (en) * 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
ES2622559T3 (es) * 2008-07-29 2017-07-06 Nerviano Medical Sciences S.R.L. Combinación terapéutica que comprende un inhibidor de cdk y un agente antineoplásico
CN102105151B (zh) * 2008-07-29 2013-12-18 内尔维阿诺医学科学有限公司 Cdk抑制剂在治疗神经胶质瘤中的应用
CN102223885B (zh) * 2008-11-24 2013-04-03 内尔维阿诺医学科学有限公司 用于治疗间皮瘤的cdk抑制剂
US8580793B2 (en) * 2009-03-20 2013-11-12 Nerviano Medical Services S.R.L. Use of kinase inhibitor for the treatment of thymoma

Also Published As

Publication number Publication date
ES2660146T3 (es) 2018-03-21
CN102428086B (zh) 2014-08-20
CN102428086A (zh) 2012-04-25
JP5801285B2 (ja) 2015-10-28
US20120041007A1 (en) 2012-02-16
JP2012525345A (ja) 2012-10-22
AR076433A1 (es) 2011-06-08
TW201043631A (en) 2010-12-16
EP2424868A1 (de) 2012-03-07
US8586598B2 (en) 2013-11-19
WO2010125004A1 (en) 2010-11-04
EP2424868B1 (de) 2018-01-10

Similar Documents

Publication Publication Date Title
HK1254345B (zh) Cdk抑制劑
HK1169408A1 (en) Cdk inhibitor salts cdk
HK1179477A1 (en) Kinase inhibitors
ZA201203842B (en) Kinase inhibitors
GB0908772D0 (en) New salts 756
EP2558099A4 (de) Kinase-inhibitoren
EP2519508A4 (de) Metalloenzymhemmerverbindungen
HK1195773A1 (zh) 抑制劑的鹽類
HK1210159A1 (en) Mk2 inhibitors mk2
GB0907886D0 (en) Corrosion inhibitor
GB0901898D0 (en) Dual calpain-ros inhibitors
EP2480076A4 (de) Imidothiazolkinaseinhibitoren
ZA201102837B (en) Phosphodiestarase inhibitors
HK1175780A1 (en) Crystalline cdc7 inhibitor salts cdc7
GB0914726D0 (en) Kinase inhibitors
GB0901900D0 (en) Dual calpain-ros inhibitors
AP2717A (en) Mono-hydrochloric salts of an inhibitor of histonedeacetylase
GB0902661D0 (en) Inhibitors
GB0903650D0 (en) Glyoalase inhibitors
GB0813850D0 (en) Salts
GB0915927D0 (en) Novel inhibitors
GB0911102D0 (en) Enzyme inhibitor
GB0904936D0 (en) Enzyme inhibitor
GB201019387D0 (en) Inhibitors
GB0908068D0 (en) Enzyme inhibitors